Across TCGA pan-cancer cohorts, SOST mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SOST data layer compared with 20 for mass-spec protein and 2 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SOST mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SOST expression acts as an unfavorable survival marker.
LSCC are the cancer types where SOST mass-spec protein most reproducibly stratifies survival.